Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04798820
Other study ID # SMC 2020-11-016-002
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 9, 2021
Est. completion date February 2024

Study information

Verified date August 2023
Source Samsung Medical Center
Contact Jae-Moon Bae, MD, Ph.D
Phone 82-2-3410-0252
Email jmoon.bae@samsung.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Radical gastrectomy has been known as the most effective treatment of curable gastric cancer.However, there is a high risk of malnutrition and weight loss after a gastrectomy which may be attributed to inadequate oral consumption, malabsorption and loss of the reservoir function of the stomach.Weight loss has been regarded as an independent risk factor for postoperative mortality and morbidity and It is also closely associated with a quality of life after surgery. No specific surgical technique has been proved to be effective in reducing postoperative weight loss and it seems like that dietary education and consultation is the best way to minimize weight loss in gastrectomy patients in clinical setting. In this regard, the investigators performed a retrospective pilot study to identify the effect of routinely performed (simplified) dietary education on nutritional status after gastrectomy, but it revealed that the effect of simplified dietary education on weight loss was not clear and the result implies that more intensive dietary education may be necessary after gastrectomy. The aim of this randomized controlled trial (RCT) is to elucidate the effect of intensive dietary education on nutritional status after gastrectomy in comparison with simplified dietary education.


Description:

Subject 1: subtotal gastrectomy group subject 2: total gastrectomy group Objectives: Primary objective: to evaluate Weight loss difference of simplified dietary education(SE) versus intensive dietary education(IE) for patients after undergoing a gastrectomy Primary endpoint: Superiority of weight loss difference (%) of IE group between post op 1mo and 12mo Secondary objectives: weight loss(%) of each subgroup, nutritional parameters (PG-SGA), Calrorie intake & dietary habits, albumin, hemoglobin, iron panel (TIBC, ferritin), Absolute lymphocyte count(ALC), vit B12, homocysteine, quality of life(QOL) change 1. Nutritional parameters (PG-SGA) 2. the amount of calorie intake (Kcal, protein) & dietary habits 3. Albumin (g/dL) 4. Hemoglobin (g/dL) 5. Iron panel [TIBC (μg/dL), Ferritin (ng/mL)] 6. Absolute lymphocyte count (ALC) (10^3/μL) 7. Vitamin B12 (pg/mL) 8. Homocysteine (μmol/L) 9. Quality of life of the patients in terms of European quality of life questionnaire (EQ-5D)


Recruitment information / eligibility

Status Recruiting
Enrollment 358
Est. completion date February 2024
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: - histologically proven primary gastric adenocarcinoma, - T1N0, T1N1, T2N0, which are assessed by computed tomography (CT) scan (AJCC 8th classification) and intraoperative surgical staging - location of primary tumor; antrum, or angle, , lower body or mid body of the stomach - No evidence of other distant metastasis, - age = 20 year old, = 75 year old - no prior or posterior treatment of chemotherapy or radiation therapy against any other malignancies - adequate organ functions defined as indicated below: 1. WBC count: 3000/mm3 ~12,000/mm3, 2. > serum Hemoglobin 8.0 g/dL 3. > serum Platelet 100 000/mm3, 4. < serum AST 100 IU/L, 5. <serum ALT 100 IU/L, 6. < Total Bilirubin 2.0 mg/dL, - written signed informed consent Exclusion Criteria: - active double cancer (synchronous double cancer and metachronous double cancer within five disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer), - gastric remnant cancer - =T3, T4 in surgical staging before resection - N2 or more (number of metastatic lymph nodes =3) in CT scan - histologically rare variants in World Health Organization (WHO) Classification such as Adenosquamous, Hepatoid, Squamous cell, Undifferentiated, neuroendocrine carcinoma and others - pregnant or breast-feeding women, - mental disorder(diagnosed with mental disorder on medical record), - unstable angina or myocardial infarction within 6 months of the trial, - unstable hypertension, - diabetes mellitus on insulin, - severe respiratory disease requiring continuous oxygen therapy, - previous upper abdominal surgery except laparoscopic cholecystectomy, - surgical complication

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Dietary education(nutritional counselling)
Dietary education provided to gastrectomy patients by dietitian.

Locations

Country Name City State
Korea, Republic of Samsung medical center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from preoperative weight change at immediate postoperative period in SE and IE groups. comparison of weight change between the two groups after surgery preoperative, immediate postoperative
Primary Change from preoperative weight change at postoperaive 1 month in SE and IE groups. comparison of weight change between the two groups after surgery preoperative, postoperative 1 month
Primary Change from preoperative weight change at postoperaive 3 months in SE and IE groups. comparison of weight change between the two groups after surgery preoperative, postoperative 3 months
Primary Change from preoperative weight change at postoperaive 6 months in SE and IE groups. comparison of weight change between the two groups after surgery preoperative, postoperative 6 months
Primary Change from preoperative weight change at postoperaive 12 months in SE and IE groups. comparison of weight change between the two groups after surgery preoperative, postoperative 12 months
Primary Change from preoperative weight change at postoperaive 18 months in SE and IE groups. comparison of weight change between the two groups after surgery preoperative, postoperative 18 months
Secondary Nutritional parameters measured by Patient-Generated Subjective Global Assessment (PG-SGA; rating A,B,C) preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary 24hrs dietary recall calculating kcal & protein intake by 24hrs dietary recall (questionnaire) preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary dietary habits number of meals, eating speed (questionnaire) preoperative, immediate postoperative, postoperative 1 months, 3 months, 6months, 12 months, 18 months
Secondary Albumin g/dL preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary Hemoglobin g/dL preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary Total iron binding capacity (TIBC) µg/dL preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary Ferritin ng/mL preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary Absolute lymphocyte count (ALC) 10^3/µL preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary Vitamin B12 pg/mL preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary Homocysteine µmol/L preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
Secondary Quality of life of the patients European quality of life questionnaire (EQ-5D); the descriptive system which comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems (labelled 1-3). preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2